National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).
Antibiotic regimen
Biologic and targeted synthetic DMARDs
Incidence
Latent tuberculosis
Tuberculosis
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
27
04
2022
accepted:
07
07
2022
pubmed:
30
8
2022
medline:
26
11
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
This publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.
Identifiants
pubmed: 36036323
doi: 10.1007/s00508-022-02062-7
pii: 10.1007/s00508-022-02062-7
pmc: PMC9684247
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-765Informations de copyright
© 2022. The Author(s).
Références
Rheumatology (Oxford). 2019 Feb 1;58(2):e3-e42
pubmed: 30137552
Medicine (Baltimore). 2010 Nov;89(6):381-402
pubmed: 21057261
BMC Infect Dis. 2019 Dec 4;19(1):1031
pubmed: 31801478
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):824-834
pubmed: 32790003
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40
pubmed: 29447987
Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34
pubmed: 27924643
Expert Opin Drug Saf. 2020 Jul;19(7):861-872
pubmed: 32552289
Ann Rheum Dis. 2016 Jun;75(6):1133-8
pubmed: 26318385
N Engl J Med. 2001 Oct 11;345(15):1098-104
pubmed: 11596589
Autoimmun Rev. 2015 Jan;14(1):1-9
pubmed: 25151975
Clin Rheumatol. 2020 Nov;39(11):3261-3276
pubmed: 32385757
Front Immunol. 2017 Nov 27;8:1633
pubmed: 29230217
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S71-S82
pubmed: 29447988
Eur Respir J. 2010 Aug;36(2):355-61
pubmed: 19926734
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
J Dtsch Dermatol Ges. 2021 Jul;19(7):1092-1117
pubmed: 34288473
N Engl J Med. 2021 Feb 18;384(7):599-609
pubmed: 33596356
Arthritis Res Ther. 2019 Apr 5;21(1):89
pubmed: 30953540
Gut. 2017 May;66(5):839-851
pubmed: 26893500
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517
pubmed: 27768242
Ther Adv Musculoskelet Dis. 2020 Jun 22;12:1759720X20930116
pubmed: 32612710
Pneumologie. 2017 Jun;71(6):325-397
pubmed: 28651293
Autoimmun Rev. 2015 Jun;14(6):503-9
pubmed: 25617816
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20
pubmed: 29459143
Health Qual Life Outcomes. 2017 Sep 21;15(1):183
pubmed: 28934978
PLoS One. 2020 Jul 15;15(7):e0235488
pubmed: 32667932
Sci Immunol. 2018 Dec 21;3(30):
pubmed: 30578351
Ann Rheum Dis. 2010 Mar;69(3):522-8
pubmed: 19854715
Arthritis Rheumatol. 2019 Jul;71(7):1125-1134
pubmed: 30771238
Arthritis Rheumatol. 2021 Jul;73(7):1108-1123
pubmed: 34101376
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):23-28
pubmed: 31662735
Expert Opin Drug Saf. 2019 May;18(5):415-425
pubmed: 31066297
Ther Apher Dial. 2019 Oct;23(5):484-485
pubmed: 30569532
JAMA Dermatol. 2021 Jan 1;157(1):43-51
pubmed: 33001147
J Bone Miner Res. 2017 Jul;32(7):1481-1485
pubmed: 28277603
J Rheumatol. 2015 Oct;42(10):1761-6
pubmed: 26276965
Lupus Sci Med. 2021 Feb;8(1):
pubmed: 33597205
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
MMWR Recomm Rep. 2020 Feb 14;69(1):1-11
pubmed: 32053584
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836